Provides methods and Pharmaceutical compositions for the treatment of inflammatory disorders, including celiac disease, Refractory celiac disease and gluten sensitivity not coeliac.Claim 1: a method for treating celiac disease or gluten sensitivity not Celiac in a subject in need,Characterized in that it comprises administering a therapeutically effective amount of an Antibody or an anti il-15 fragment Antigen Binding to the same subject.Where the therapeutically effective amount includes between 1 and 20 each Unit dose administered At intervals of approximately between 1 and 12 Weeks.Where each Unit dose includes independently between approximately 50 and 1000 mg, preferably between 75 to 600 mg, more preferably approximately 75 mg, 150 mg,Approximately 300 mg or 600 mg or approximately 450 mg of il-15 Antibody or Antigen binding Fragment.26: the pharmaceutical Composition of claim claim 23 or 24,Wherein the Antibody has a variable region of heavy chain is the amino acid sequence of SEQ ID no. 2Or a sequence has at least 80% Sequence identity with the same.27: the pharmaceutical Composition of claim claim 25,Wherein the Antibody has a variable region of light chain is the amino acid sequence of SEQ ID no. 4Or a sequence has at least 80% Sequence identity with the same.Se proveen métodos y composiciones farmacéuticas para el tratamiento de trastornos inflamatorios, en particular enfermedad celíaca, enfermedad celíaca refractaria y sensibilidad al gluten no celíaca. Reivindicación 1: Un método para tratar enfermedad celíaca o sensibilidad al gluten no celíaca en un sujeto que lo necesite, caracterizado porque comprende administrar una cantidad terapéuticamente eficaz de un anticuerpo anti-IL-15 o un fragmento de unión a antígeno del mismo al sujeto, en donde la cantidad terapéuticamente eficaz comprende entre 1 y 20 dosis unitarias cada una administrada a intervalos de aproximadamente entre 1 y 12 semanas, en donde cada dosis unitaria comprende en forma independiente
